What Can We Learn from the Evolution of Protein-Ligand Interactions to Aid the Design of New Therapeutics?

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Higueruelo, Alicia P ^a   Schreyer, Adrian ^a   Bickerton, G Richard J ^a,c   Blundell, Tom L ^a   Pitt, Will R ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; LIGAND BINDING; LIPOPHILICITY; MOLECULAR EVOLUTION; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR RECOGNITION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; STRUCTURE ANALYSIS;

DRUG DESIGN; EVOLUTION, MOLECULAR; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN BINDING; PROTEINS; SOFTWARE; WATER;

EID: 84871126379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051742     Document Type: Article

References (39)

1. Garnier JP, (2008) Rebuilding the R&D engine in big pharma. Harv Bus Rev 86: 68-70.
2. Leeson P, Springthorpe B, (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6: 881-890.
3. Keserü GM, Makara GM, (2009) The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 8: 203-212.
4. Gleeson MP, Hersey A, Montanari D, Overington J, (2011) Probing the links between in vitro potency, ADMET and physicochemical parameters. Nature Reviews Drug Discovery 10: 197-208.
5. Leeson PD, St-Gallay SA, (2011) The influence of the 'organizational factor' on compound quality in drug discovery. Nat Rev Drug Discov 10: 749-765.
6. Dobson PD, Kell DB, (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7: 205-220.
7. Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, et al. (2010) Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 9: 597-614.
8. Hann MM, (2011) Molecular obesity, potency and other addictions in drug discovery. MedChemComm 2: 349-355.
9. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046-1051.
10. Deu E, Verdoes M, Bogyo M, (2012) New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol 19: 9-16.
11. Wells J, McClendon C, (2007) Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
12. Cochran AG, (2000) Antagonists of protein-protein interactions. Chem Biol 7: R85-R94.
13. Higueruelo AP, Schreyer A, Bickerton GRJ, Pitt WR, Groom CR, et al. (2009) Atomic Interactions and Profile of Small Molecules Disrupting Protein-Protein Interfaces: the TIMBAL Database. Chem Biol Drug Des 74: 457-467.
14. Schreyer A, Blundell T, (2009) CREDO: A Protein-Ligand Interaction Database for Drug Discovery. Chem Biol Drug Des 73: 157-167.
15. Bickerton GR, Higueruelo AP, Blundell TL, (2011) Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database. BMC Bioinformatics 12: 313.
16. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
17. Olsson TSG, Williams MA, Pitt WR, Ladbury JE, (2008) The Thermodynamics of Protein-Ligand Interaction and Solvation: Insights for Ligand Design. J Mol Biol 384: 1002-1017.
18. Hann MM, Leach AR, Harper G, (2001) Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery. J Chem Inf Comput Sci 41: 856-864.
19. Congreve M, Chessari G, Tisi D, Woodhead AJ, (2008) Recent Developments in Fragment-Based Drug Discovery. J Med Chem 51: 3661-3680.
20. An J, Totrov M, Abagyan R, (2005) Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes. Molecular & Cellular Proteomics 4: 752-761.
21. Kahraman A, Morris RJ, Laskowski RA, Thornton JM, (2007) Shape variation in protein binding pockets and their ligands. J Mol Biol 368: 283-301.
22. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, et al. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-2623.
23. Ferenczy GG, Keseru{double acute} GM, (2010) Thermodynamics guided lead discovery and optimization. Drug Discov Today 15: 919-932.
24. Murzin A, Brenner S, Hubbard T, Chothia C, (1995) SCOP: a structural classification of proteins database for the investigation of sequences and structures. J Mol Biol 247: 536-540.
25. Wang R, Fang X, Lu Y, Wang S, (2004) The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem 47: 2977-2980.
26. Kuntz ID, Chen K, Sharp KA, Kollman PA, (1999) The maximal affinity of ligands. Proc Natl Acad Sci U S A 96: 9997-10002.
27. Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC, (2005) The structure of interleukin-2 complexed with its alpha receptor. Science 308: 1477-1480.
28. Thanos CD, Randal M, Wells JA, (2003) Potent Small-Molecule Binding to a Dynamic Hot Spot on IL-2. J Am Chem Soc 125: 15280-15281.
29. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, et al. (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14: 1711-1713.
30. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
31. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, et al. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48: 909-912.
32. Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, et al. (2000) Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408: 1004-1008.
33. Oost TK, Sun C, Armstrong RC, Al-Assaad AS, Betz SF, et al. (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47: 4417-4426.
34. Mosyak L, Zhang Y, Glasfeld E, Haney S, Stahl M, et al. (2000) The bacterial cell-division protein ZipA and its interaction with an FtsZ fragment revealed by X-ray crystallography. EMBO J 19: 3179-3191.
35. Rush TS, Grant JA, Mosyak L, Nicholls A, (2005) A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 48: 1489-1495.
36. Eck MJ, Sprang SR, (1989) The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 264: 17595-17605.
37. He M, Smith A, Oslob J, Flanagan W, Braisted A, et al. (2005) Small-Molecule Inhibition of TNF-alpha. Science 310: 1022-1025.
38. Rustandi RR, Baldisseri DM, Weber DJ, (2000) Structure of the negative regulatory domain of p53 bound to S100B(betabeta). Nat Struct Biol 7: 570-574.
39. Charpentier T, Wilder P, Liriano M, Varney K, Zhong S, et al. (2009) Small Molecules Bound to Unique Sites in the Target Protein Binding Cleft of Calcium-Bound S100B As Characterized by Nuclear Magnetic Resonance and X-ray Crystallography. Biochemistry 48: 6202-6212.